Richa Gupta1, Raj Kumar2, Lokesh Chauhan3. 1. Department of Glaucoma, CL Gupta Eye Institute, Ram Ganga Vihar, Phase 2(Ext), Moradabad, 244001, India. richa_kmc@rediffmail.com. 2. Department of Optometry and Visual Sciences, CL Gupta Eye Institute, Ram Ganga Vihar, Phase 2(Ext), Moradabad, 244001, India. 3. Department of Clinical Research, C L Gupta Eye Institute, Ram Ganga Vihar, Phase 2(Ext), Moradabad, 244001, India.
Abstract
PURPOSE: To evaluate morphometric variables, like anterior chamber angle (ACA), anterior chamber volume (ACV) and central anterior chamber depth (CACD) after pilocarpine administration and after prophylactic laser peripheral iridotomy (LPI) in eyes with primary angle-closure disease (PACD). DESIGN: Prospective cohort study METHODS: Ninety-one eyes of 91 patients with narrow angles were consecutively enrolled in this prospective interventional study. All patients were classified into primary angle-closure suspect (PACS), primary angle-closure (PAC) and primary angle-closure glaucoma (PACG). If both eyes were eligible, one eye was randomly selected for study inclusion. ACV, ACD and ACA were evaluated using Scheimpflug imaging technology at three time points: at baseline (T0), 45 min after application of pilocarpine before LPI (T1) and at one-month post-LPI (T2). RESULTS: PACS, PAC and PACG groups included 25 (27.4%), 24 (26.3%) and 42 (46.1%) eyes, respectively. At both time points T1 and T2, mean pupil diameter, ACV and ACA changed significantly (P = 0.00). In all subgroups, ACD decreased significantly at T1 and then increased significantly at T2. ACA was widened by 6 degrees in angles < 26 degrees as compared to 3 degrees in > 26 degrees eyes. In PACG group, mean ACV increased significantly between T0 and T2 (P = 0.0). Other parameters like mean cornea volume (P = 0.27), central corneal thickness (P = 0.29) showed no significant change between time points (T0, T1 and T2). Pilocarpine instillation caused a significant increase in ACA, ACV and ACD CONCLUSION: Scheimpflug imaging detected significant changes in ACD post-LPI and post-pilocarpine in all groups. However, ACV changed significantly only in PACS and PACG. CLINICAL TRIALS REGISTRATION: Gels and blots/image manipulation: Author declares that the final image submitted represent the original data. All unprocessed images are with corresponding author and will make available if required.
PURPOSE: To evaluate morphometric variables, like anterior chamber angle (ACA), anterior chamber volume (ACV) and central anterior chamber depth (CACD) after pilocarpine administration and after prophylactic laser peripheral iridotomy (LPI) in eyes with primary angle-closure disease (PACD). DESIGN: Prospective cohort study METHODS: Ninety-one eyes of 91 patients with narrow angles were consecutively enrolled in this prospective interventional study. All patients were classified into primary angle-closure suspect (PACS), primary angle-closure (PAC) and primary angle-closure glaucoma (PACG). If both eyes were eligible, one eye was randomly selected for study inclusion. ACV, ACD and ACA were evaluated using Scheimpflug imaging technology at three time points: at baseline (T0), 45 min after application of pilocarpine before LPI (T1) and at one-month post-LPI (T2). RESULTS: PACS, PAC and PACG groups included 25 (27.4%), 24 (26.3%) and 42 (46.1%) eyes, respectively. At both time points T1 and T2, mean pupil diameter, ACV and ACA changed significantly (P = 0.00). In all subgroups, ACD decreased significantly at T1 and then increased significantly at T2. ACA was widened by 6 degrees in angles < 26 degrees as compared to 3 degrees in > 26 degrees eyes. In PACG group, mean ACV increased significantly between T0 and T2 (P = 0.0). Other parameters like mean cornea volume (P = 0.27), central corneal thickness (P = 0.29) showed no significant change between time points (T0, T1 and T2). Pilocarpine instillation caused a significant increase in ACA, ACV and ACD CONCLUSION: Scheimpflug imaging detected significant changes in ACD post-LPI and post-pilocarpine in all groups. However, ACV changed significantly only in PACS and PACG. CLINICAL TRIALS REGISTRATION: Gels and blots/image manipulation: Author declares that the final image submitted represent the original data. All unprocessed images are with corresponding author and will make available if required.
Authors: Nazlee Zebardast; Srinivasan Kavitha; Palaniswamy Krishnamurthy; David S Friedman; Monisha E Nongpiur; Tin Aung; Harry A Quigley; Pradeep Y Ramulu; Rengaraj Venkatesh Journal: Ophthalmology Date: 2016-10-07 Impact factor: 12.079
Authors: Alicia C How; Mani Baskaran; Rajesh S Kumar; Mingguang He; Paul J Foster; Raghavan Lavanya; Hon-Tym Wong; Paul T K Chew; David S Friedman; Tin Aung Journal: Ophthalmology Date: 2012-03-10 Impact factor: 12.079
Authors: Winifred P Nolan; Jovina L See; Paul T K Chew; David S Friedman; Scott D Smith; Sunita Radhakrishnan; Ce Zheng; Paul J Foster; Tin Aung Journal: Ophthalmology Date: 2006-10-27 Impact factor: 12.079